On 1 November, cannabis-based epilepsy treatment Epidiolex went on sale throughout the US, having become the first drug incorporating non-synthetic cannabidiol to win FDA approval over the summer. In our latest in-house Q&A, PLN caught up with Epidiolex manufacturer GW Pharmaceutical’s general counsel Iain Ward.